Market Newsdesk

TARRYTOWN, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) — Prestige Consumer Healthcare Inc. (the “Company” or “Prestige”) (NYSE: PBH) today announced that Chief Financial Officer Christine Sacco’s responsibilities have been expanded to include the role of Chief Operating Officer, effective immediately. In this enhanced position as COO/CFO, Ms. Sacco will oversee the Company’s supply chain, in addition to her existing responsibilities. Ms. Sacco will continue to report to Ron Lombardi, Chief Executive Officer of Prestige.

“Chris’ strategic leadership and deep understanding of our business has been instrumental in our growth and success over her 8 years as CFO,” said Ron Lombardi. “This expanded COO/CFO role positions us to further enhance execution of our strategic initiatives and drive operational excellence across the organization. Her proven track record in finance combined with her experience working closely with our supply chain operations uniquely positions her to drive further operational excellence and long-term organic and M&A growth for our Company in this expanded role.”

A seasoned executive with more than 27 years of leadership experience in the consumer products and specialty pharma space, Ms. Sacco has served as the Company’s Chief Financial Officer since 2016. During her tenure, she has made vital contributions to the Company’s strategic transformation and financial success. Under her financial leadership, the Company has achieved strong sales, earnings and cash flow growth over the past 8 years while positioning Prestige with significant future capital allocation flexibility to drive further shareholder value.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare is a leading consumer healthcare products company with sales throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat^® and Summer’s Eve^® women’s health products, BC^® and Goody’s^® pain relievers, Clear Eyes^® and TheraTears^® eye care products, DenTek^® specialty oral care products, Dramamine^® motion sickness treatments, Fleet^® enemas and glycerin suppositories, Chloraseptic^® and Luden’s^® sore throat treatments and drops, Compound W^® wart treatments, Little Remedies^® pediatric over-the-counter products, Boudreaux’s Butt Paste^® diaper rash ointments, Nix^® lice treatment, Debrox^® earwax remover, Gaviscon^® antacid in Canada, and Hydralyte^® rehydration products and the Fess^® line of nasal and sinus care products in Australia. Visit the Company’s website at www.prestigeconsumerhealthcare.com.

Investor Relations Contact

Phil Terpolilli, CFA, 914-524-6819
[email protected]

Source: Prestige Consumer Healthcare Inc.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b8a99b5b-fd18-4d27-9a39-e14d1986df82

BURLINGTON, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC) (“Cerence AI” or “the Company”), a global leader in AI for transportation, announced today that it will be presenting at the 27^th Annual Needham Growth Conference on Tuesday, January 14, 2025 at 12:45 p.m. Eastern Time. The fireside chat format will feature Brian Krzanich and Tony Rodriquez, Cerence AI’s CEO and CFO, respectively.

The presentation will be webcast and can be accessed in the “Events” tab under the “Investors” section of the Company’s website at https://www.cerence.com/investors/events-and-resources. 

The webcast replay will be available on the Company’s website at www.cerence.ai.

About Cerence Inc.

Cerence Inc. (NASDAQ: CRNC) is a global industry leader in creating intuitive, seamless, AI-powered experiences across automotive and transportation. Leveraging decades of innovation and expertise in voice, generative AI, and large language models, Cerence powers integrated experiences that create safer, more connected, and more enjoyable journeys for drivers and passengers alike. With more than 500 million cars shipped with Cerence technology, the company partners with leading automakers, transportation OEMs, and technology companies to advance the next generation of user experiences. Cerence is headquartered in Burlington, Massachusetts, with operations globally and a worldwide team dedicated to pushing the boundaries of AI innovation. For more information, visit www.cerence.ai.

Contact Information:
Jason Gold | Email: [email protected] 

JACKSONVILLE, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) — Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT), is excited to announce the successful closing of an Asset Management Agreement (“AMA”) through its operating subsidiary, Duos Energy Corporation. The AMA – announced on November 20, 2024 – encompasses the deployment and operation of a fleet of 30 mobile gas-powered turbines and associated balance-of-plant inventory (“the Assets”), collectively capable of generating 850 megawatts of power, which have been acquired by funds managed by affiliates of Fortress Investment Group (“Fortress”).

The assets will be managed in partnership with affiliates of Fortress, and are immediately deployable, providing a fast-track solution to meet the urgent energy demands of data centers and other industries. The transaction was finalized on December 31, 2024, following the fulfillment of customary closing conditions and regulatory approvals.

Fortress has entered into this strategic agreement with Duos Energy Corporation, whose leadership includes the former executive management team of APR Energy – from which the Assets were acquired. Duos Energy will oversee the management and deployment of the mobile gas-powered turbine fleet to meet growing energy demands across critical sectors, including Data Centers such as those deployed by subsidiary Duos Edge AI as well as emergency power solutions.

Further solidifying this partnership, Duos has secured a 5% equity stake in the parent of the owner of the assets. This equity position reflects Duos’ integral role in the commercialization, operation and management of these critical power assets.

“Our customers are looking for flexible and dependable energy options as they build out critical infrastructure,” said Chuck Ferry, Chief Executive Officer of Duos. “These assets, coupled with our operational excellence, provide a pathway to meet these demands without the delays or constraints of traditional energy sources.”

This agreement reinforces Duos’ strategic focus on addressing the evolving power needs of data centers, industrial facilities, and international energy markets. Duos Energy is in active discussions with U.S.-based data center developers and international energy projects for immediate deployment of the turbines. The company’s mission is to deliver agile and scalable energy solutions, supporting its customers’ growth while building out a robust energy business aligned with Duos’ long-term vision.

To learn more about Duos Energy Corporation, visit: www.duosenergycorp.com
To learn more about Fortress Investment Group, visit: www.fortress.com
To learn more about Duos Technologies, visit www.duostechnologies.com

About Duos Energy Corporation
Duos Energy Corporation, a subsidiary of Duos Technologies Group, Inc. (Nasdaq: DUOT), focuses on developing, owning, and operating sustainable energy projects to power Edge Data Centers and critical infrastructure industrial facilities across the United States. Specializing in clean-burning natural gas generation and green technologies, the company offers rapid deployment of dedicated off-grid power plants. With extensive industry experience, Duos Energy is dedicated to providing fast-track, reliable, and eco-friendly energy solutions that support mission-critical operations. For more information, visit www.duosenergycorp.com.

About Fortress Investment Group
Fortress Investment Group LLC is a leading, highly diversified global investment manager. Founded in 1998, Fortress manages $49 billion of assets under management as of September 30, 2024, on behalf of approximately 2,000 institutional clients and private investors worldwide across a range of credit and real estate, private equity and permanent capital investment strategies. For more information please visit www.fortress.com.

About Duos Technologies Group, Inc.

Duos Technologies Group, Inc. (Nasdaq: DUOT), based in Jacksonville, Florida, through its wholly owned subsidiaries, Duos Technologies, Inc., Duos Edge AI, Inc., and Duos Energy Corporation, designs, develops, deploys and operates intelligent technology solutions for Machine Vision and Artificial Intelligence (“AI”) applications including real-time analysis of fast-moving vehicles, Edge Data Centers and power consulting. For more information, visit www.duostech.com, www.duosedge.ai and www.duosenergycorp.com.

Forward-Looking Statements


This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our plans, strategies and prospects — both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as “believe,” “expect,” “anticipate,” “should,” “planned,” “will,” “may,” “intend,” “estimated” and “potential,” among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. All forward-looking statements attributable to Duos Technologies Group, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1a1d5524-9e14-4b78-82f9-a539625b205d

This press release was published by a CLEAR® Verified individual.

Contacts

Corporate
Fei Kwong
Director, Corporate Communications
Duos Technologies Group, Inc. (Nasdaq: DUOT)
+1.904.652.1625
[email protected]
[email protected]

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 4:30pm PT in San Francisco.

To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.

About Ardelyx, Inc.

Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA^® (tenapanor) and XPHOZAH^® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL^® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:

Caitlin Lowie
[email protected]

CHARLESTOWN, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired employee.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Solid Biosciences

Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:

Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
[email protected]

Media Contact:

Glenn Silver
FINN Partners
[email protected]

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company.

“We are pleased to welcome Lori as chair of the board,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT. “In the four years that Lori has served as a board member, she has provided invaluable guidance based on her leadership experience driving strategic and commercial success in both biotech and pharmaceutical companies. We look forward to her increased involvement as we pursue late-stage development and potential commercialization in the field of inflammatory diseases. We also thank Bill for his nine years on our board providing steady and wise counsel.”

“It has been an honor and a pleasure to serve as chair of the RAPT board,” said Mr. Rieflin. “I have confidence in the board and the management team and believe that Lori has the skills and experience to help guide RAPT into the future.”

Ms. Lyons-Williams, an industry veteran with more than 20 years of experience spanning multinational pharmaceutical and emerging biotech companies, is President and CEO of Abdera Therapeutics, a biopharmaceutical company leveraging antibody engineering to design and develop new precision radiopharmaceuticals for cancer. Previously, Lori was president and chief operating officer of Neumora Therapeutics and earlier served as chief commercial officer of Dermira, a biopharmaceutical company focused on immunology and medical dermatology, until its acquisition by Eli Lilly. Before that, she spent 15 years at Allergan in roles of increasing responsibility, where she successfully launched numerous commercial products, including multiple indications of BOTOX®. Lori currently serves on the boards of directors of Abdera Therapeutics and Contineum Therapeutics (Nasdaq: CTNM); she joined the RAPT board of directors in 2021.

“I am excited to partner with Brian and his team as RAPT evolves as a company. I am particularly encouraged by the broad opportunity for RPT904 in food allergy and other allergic diseases as well as the promise and potential of the company’s CCR4-targeted drug candidates,” said Ms. Lyons-Williams. “I look forward to collaborating with my fellow board members as we continue to advance the company.”

About RAPT Therapeutics, Inc.

RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with inflammatory and immunological diseases. The company leverages its proprietary discovery and development platform to advance both biologics and selective small molecules aimed at normalizing critical immune drivers underlying these conditions.

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the clinical development of RPT904, the commercial prospects of RPT904 and other statements that are not historical fact. Factors that may cause actual results to differ materially from the plans, intentions and expectations disclosed in these forward-looking statements include uncertainties inherent in the initiation, progress and completion of clinical trials and clinical development of RAPT’s product candidates; the risk that clinical trials may have unsatisfactory outcomes; risks associated with preclinical development of product candidates; risks that efforts to secure licensing and other business development opportunities may not be successful; and other important factors, detailed in RAPT’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements.

Investor Contact:

Sylvia Wheeler
[email protected]

Media Contact:        
Aljanae Reynolds
[email protected]

SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its Quality, Innovation, and Corporate Responsibility Report, highlighting key efforts that reflect its commitment to conduct operations as a responsible corporation in the healthcare industry.

“Quality, innovation and corporate responsibility are at the heart of what we do at Myriad Genetics,” said Paul J. Diaz, President and CEO, Myriad Genetics. “In concert with our mission to advance health and well-being for all, we continue to execute our long-term strategic growth plan, driving sustained progress and impact. This report reflects our progress on how we are making genetic testing more accessible, helping patients take more control of their health, and enabling providers to better prevent and treat disease.”

Highlights of the report, which reflect the 21-month period of Jan. 1, 2023 through Sept. 30, 2024 (the “Reporting Period”), include:

• Continued operational excellence: Through a quality management system that documents our best practices, Myriad shared success in several categories including 88% of samples being processed within what we believe are industry-leading turnaround-times. Further, the company achieved a 72 net promoter score among current providers across its testing portfolio through July 2024.
• Commitment to innovation: Myriad continues to develop new technologies like molecular residual disease (MRD) assay and bring innovations to existing products. Its Labs of the Future initiative has resulted in modernized facilities that are expected to yield improved workflows, faster turnaround times and reduced operating costs.
• Being a good corporate partner: In addition to corporate governance, Myriad showcased its retention and recruitment, sustainability and community relations efforts. From a people standpoint, in 2024, 84% of employees said Myriad is a great place to work, which was 27 percentage points higher than the typical U.S. company. Further, in the Reporting Period, the company recycled 46.9 tons of plastic from its Salt Lake City laboratories.

For more information about Myriad’s quality, innovation and corporate responsibility, please read the report here.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Safe Harbor Statement   

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that the company’s Labs of the Future are expected to yield improved workflows, faster turnaround times and reduced operating costs. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. 

Investor Contact 

Matt Scalo 
(801) 584-3532 
[email protected] 

Media Contact 

Glenn Farrell 
(385) 318-3718 
[email protected]

HOLLYWOOD, FL, Jan. 06, 2025 (GLOBE NEWSWIRE) — Healthy Choice Wellness Corp. (“HCWC” or the “Company”) (NYSEAM: HCWC), a holding company operating 19 natural and organic grocery stores across six states, today announced significant growth in sales and gross margin in its fourth quarter and year ended December 31, 2024 results.

Key Fourth Quarter and Full-Year 2024 Sales and Gross Margin Highlights:

• Record Sales Growth: The Company achieved record sales of $19.6 million for the three months ended December 31, 2024, representing a 23.9% increase year-over-year. Full-year 2024 sales reached $69.3 million, a 24.5% increase compared to 2023.
• Strong Gross Margin Performance: The Company generated approximately $7.4 million in gross profit for the fourth quarter and $26.3 million for the full year 2024. This represents a gross margin increase of approximately $1.7 million for the fourth quarter and $6.0 million for the full year.

Jeffrey Holman, HCWC CEO and Chairman, commented, “Healthy Choice Wellness Corp.’s record 2024 sales and gross margin are a testament to our commitment to create value for our customers and shareholders. This strong performance validates our strategic approach and underscores our ability to drive profitable growth. We are confident that our continued investments in future acquisitions, coupled with strategic initiatives and operational efficiencies, leaves us well positioned to deliver compelling financial returns in 2025 and beyond.”

About Healthy Choice Wellness Corp.

Healthy Choice Wellness Corp. is a holding company focused on providing consumers with healthier daily choices with respect to nutrition and other lifestyle alternatives. 

Through its wholly owned subsidiaries, the Company operates:

		Ada’s Natural Market, a natural and organic grocery store offering fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health & beauty products and natural household items (www.Adasmarket.com).
		Paradise Health & Nutrition’s three stores that likewise offer fresh produce, bulk foods, vitamins, and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health & beauty products and natural household items (www.ParadiseHealthDirect.com).
		Mother Earth’s Storehouse, an organic and health food and vitamin store in New York’s Hudson Valley, which has been in existence for over 40 years (www.MotherEarthStorehouse.com).
		Greens Natural Foods’ eight stores in New York and New Jersey, offering a selection of 100% organic produce and all-natural, non-GMO groceries and bulk foods; a wide selection of local products; an organic juice and smoothie bar; a fresh foods department, which offers fresh and healthy “grab & go” foods; a full selection of vitamins & supplements; as well as health and beauty products. (www.Greensnaturalfoods.com).
		Ellwood Thompson’s, an organic and natural health food and vitamin store located in Richmond, Virginia (www.ellwoodthompsons.com). GreenAcres Market, an organic and natural health food and vitamin chain with five store locations in Kansas and Oklahoma. GreenAcres Market is a chain of premier natural foods stores, offering organic and all natural products and vitamins from both top national brands as well as locally sourced specialty brand (www.greenacres.com).

Through its wholly owned subsidiary, Healthy U Wholesale, the Company sells vitamins and supplements, as well as health, beauty and personal care products on its website www.TheVitaminStore.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of that term in the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Additional written or oral forward-looking statements may be made by the Company from time to time in filings with the Securities and Exchange Commission (SEC) or otherwise. Statements contained in this press release that are not historical facts are forward looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and are based on management’s estimates, assumptions and projections and are not guarantees of future performance. The Company assumes no obligation to update these statements. Forward looking statements may include, but are not limited to, projections or estimates of revenue, income, or loss, exit costs, cash flow needs and capital expenditures, statements regarding future operations, expansion or restructuring plans, including our recent exit from, and winding down of our wholesale distribution operations. In addition, when used in this release, the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” and “plans” and variations thereof and similar expressions are intended to identify forward looking statements.

Factors that may affect our future results of operations and financial condition include, but are not limited to, fluctuations in demand for our products, the introduction of new products, our ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of our liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in our filings with the SEC.

Contact Information

Healthy Choice Wellness Corp.
3800 North 28th Way, Hollywood, FL 33020
305-600-5004
Email: [email protected]

HOLLYWOOD, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) — NV5, a provider of technology, certification, and consulting solutions, announced today that it intends to repurchase up to $20 million of NV5’s common stock during the next open trading period. The repurchase is in accordance with the $100 million stock repurchase program that was previously approved by the NV5 Board of Directors.

“This share repurchase program reflects NV5’s strong financial position and our anticipation of accelerated organic growth and profitability of NV5’s operations,” said Dickerson Wright, PE, Executive Chairman of NV5. “The current valuation of NV5’s stock creates a unique opportunity for NV5 to utilize its excess cash flows to repurchase shares. We also have a strong mergers and acquisitions pipeline, and we expect M&A, along with strong organic growth, to continue contributing to NV5’s growth.”

NV5’s next open trading period will take place following the announcement of NV5’s 2024 fourth quarter and full-year financial results. The number of shares repurchased will depend on a number of factors including share price.

About NV5

NV5 Global, Inc. (NASDAQ: NVEE) is a provider of technology, certification, and consulting solutions for public and private sector clients supporting utility, infrastructure, and building assets and systems. The Company primarily focuses on six business verticals: Utility services, infrastructure engineering, construction quality assurance, buildings & technology, environmental health sciences, and geospatial services. NV5 operates out of more than 100 offices nationwide and abroad. For additional information, please visit the Company’s website at www.NV5.com. Also visit the Company on Twitter, LinkedIn, Facebook, and Vimeo.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The Company cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements contained in this news release. Such factors include: (a) changes in demand from the local and state government and private clients that we serve; (b) general economic conditions, nationally and globally, and their effect on the market for our services; (c) competitive pressures and trends in our industry and our ability to successfully compete with our competitors; (d) changes in laws, regulations, or policies; and (e) the “Risk Factors” set forth in the Company’s most recent SEC filings. All forward-looking statements are based on information available to the Company on the date hereof, and the Company assumes no obligation to update such statements, except as required by law.

Investor Relations Contact

NV5 Global, Inc.
Jack Cochran
Vice President, Marketing & Investor Relations
Tel: +1-954-637-8048
Email: [email protected]

Source: NV5 Global, Inc.

SUNNYVALE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) — Real-Time Innovations (RTI), the infrastructure software company for smart-world systems, today announced XPENG has selected RTI Connext Drive^® to provide the core communication technology for its next generation E/E vehicle architecture. Starting with the 2026 production models, Connext Drive will manage the complex data distribution in XPENG vehicles, supporting the company’s mission to create smarter, more efficient and future-ready vehicles equipped with the latest technologies.

“XPENG required a communication framework that supports a unified architecture across all of our designs — one that could manage the intense data requirements across a diverse range of XPENG models, from high-end to entry-level vehicles,” said Yu Peng, Vice President at XPENG. “RTI Connext Drive stood out as a flexible, highly-reliable and production-proven middleware. In addition, RTI’s impressive leadership within the DDS standard domain and its decades of experience with complex systems will help XPENG accelerate design and reduce risk as we develop our future vehicles.”

Based on the Data Distribution Service (DDS™) standard, Connext Drive is a software framework that handles large volumes of data in real time, ensuring seamless communication between vehicle systems, regardless of supplier. Its platform-independent architecture and ability to manage complex communication flow provides the data backbone to integrate and run automotive systems, such as advanced driver-assistance systems (ADAS) or autonomous driving features, without overhauling existing infrastructure. This adaptability ensures that XPENG can incorporate cutting-edge technologies into future models without the need to re-write code.

“As XPENG continues to push the boundaries of automotive innovation, RTI is proud to provide the communication middleware for all XPENG models, starting in 2026,” said Thomas Bloor, Director of Automotive Business at RTI. “Connext Drive provides the platform independence and reliability needed to enable communications across XPENG’s vehicle range, while also offering the scalability and flexibility to enable advanced AI solutions as their technology evolves.”

XPENG is a leading Chinese electric vehicle (EV) manufacturer, dedicated to creating smart, connected, and sustainable mobility solutions. The company combines cutting-edge technology with advanced manufacturing to deliver high-performance electric vehicles that cater to a wide range of customers, from high-end models to more accessible options. With a strong focus on innovation, XPENG continues to drive the future of mobility with next-generation vehicles that incorporate AI, autonomous driving, and other smart features, offering a seamless and connected driving experience.

For more information about RTI Connext Drive, please visit this link.

About RTI

Real-Time Innovations (RTI) is the infrastructure software company for smart-world systems. RTI Connext^® is the world’s leading software framework for intelligent distributed systems. Uniquely, Connext users can build systems that combine advanced sensing, fast control, and AI algorithms.

With 2,000 customer designs, RTI excels at getting customers to production. RTI software runs over 250 autonomous vehicle programs, supports dozens of automotive ADAS and software-defined architectures, controls the largest power plants in North America, integrates over 400 major defense programs, drives a new generation of MedTech systems and robotics, and underlies Canada’s air traffic control and NASA’s launch control systems.

RTI runs a smarter world.

RTI is the market leader in products compliant with the Data Distribution Service (DDS™) standard. RTI is privately held and headquartered in Silicon Valley with regional offices in Colorado, Spain, and Singapore.

Download a free trial of the latest, fully-functional Connext software today: www.rti.com/downloads

About XPENG

Founded in 2014, XPENG is a leading Chinese AI-driven mobility company that designs, develops, manufactures, and markets Smart EVs, catering to a growing base of tech-savvy consumers. With the rapid advancement of AI, XPENG aspires to become a global leader in AI mobility, with a mission to drive the Smart EV revolution through cutting-edge technology, shaping the future of mobility.

To enhance the customer experience, XPENG develops its full-stack advanced driver-assistance system (ADAS) technology and intelligent in-car operating system in-house, along with core vehicle systems such as the powertrain and electrical/electronic architecture (EEA). Headquartered in Guangzhou, China, XPENG also operates key offices in Beijing, Shanghai, Silicon Valley, and Amsterdam. Its Smart EVs are primarily manufactured at its facilities in Zhaoqing and Guangzhou, Guangdong province.

XPENG is listed at the New York Stock Exchange (NYSE: XPEV) and Hong Kong Exchange (HKEX: 9868).

For more information, please visit https://www.xpeng.com/.

Media Contacts:
Tiffany Yang, RTI
Public Relations, RTI
[email protected]